HR Execs on the Move

Regeneron

www.regeneron.com

 
Get in the Ideas Business. At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work together to discover, invent, and develop biopharmaceutical medicines, we`re creating whole new ways of thinking about science, manufacturing and commercialization. And whole new ways of thinking about health. So connect with us. Tell us about you. Learn more about our life-changing medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for more information on how to engage with Regeneron on social media. An important note about privacy: Regeneron is ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.regeneron.com
  • 777 Old Saw Mill River Road
    Tarrytown, NY USA 10591
  • Phone: 914.847.7000

Executives

Name Title Contact Details
Tracey Stevens
 Senior Director, Laboratory and Site Profile
Christopher Fenimore
 Senior Vice President, Finance And Chief Financial Officer Profile
David Dix
 Associate Director, IOPS Finance Profile
Dan Baioni
 Director of Finance And Administration Profile
Pascal Bouffard
 Director R&D Operations Profile

Similar Companies

SABiosciences Corporation

SABiosciences Corporation is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Q Therapeutics

Q Therapeutics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gameto

Gameto is a biotechnology company that uses cell engineering to develop novel therapeutics for the diseases of the female reproductive system.

Tasso

Tasso is changing the way that care is delivered with simple, virtually painless, clinical-grade diagnostic testing that can be done from home.

Genmab

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.